Next Article in Journal
Genetic and Drug Inhibition of LDH-A: Effects on Murine Gliomas
Next Article in Special Issue
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Previous Article in Journal
MEOX2 Regulates the Growth and Survival of Glioblastoma Stem Cells by Modulating Genes of the Glycolytic Pathway and Response to Hypoxia
Previous Article in Special Issue
A Prognostic Model Using Post-Steroid Neutrophil-Lymphocyte Ratio Predicts Overall Survival in Primary Central Nervous System Lymphoma
 
 
Article
Peer-Review Record

Circulating microRNAs in Cerebrospinal Fluid and Plasma: Sensitive Tool for Detection of Secondary CNS Involvement, Monitoring of Therapy and Prediction of CNS Relapse in Aggressive B-NHL Lymphomas

Cancers 2022, 14(9), 2305; https://doi.org/10.3390/cancers14092305
by Pavle Krsmanovic 1,†, Heidi Mocikova 2,†, Kamila Chramostova 1, Magdalena Klanova 1,3, Marie Trnkova 3, Michal Pesta 4, Peter Laslo 5, Robert Pytlik 6, Tomas Stopka 3,7, Marek Trneny 3 and Vit Pospisil 1,*
Reviewer 1:
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Reviewer 4: Anonymous
Cancers 2022, 14(9), 2305; https://doi.org/10.3390/cancers14092305
Submission received: 15 March 2022 / Accepted: 7 April 2022 / Published: 6 May 2022
(This article belongs to the Special Issue Non-Hodgkin Lymphomas)

Round 1

Reviewer 1 Report

Authors have addressed the comments very nicely. Paper can be accepted now

Reviewer 2 Report

Authors argued and have modified the mansucript according to the comments adressed. Few comments:

- OS charts of MCL should be added in the supplement figures.

- line 245: n=55 secondary CNS. This is different from methods section (n=54)

  • line 247: n=15 SCNSL instead of n=13 in method section. and B-NHL= 13 and not 12 (9+4)
  • -line 340-341, reformulate...
  • - line 493: tipo: "prediction"
  • - line 544: tipo " included"
  • - line 587: "BBB"?

Reviewer 3 Report

These comments however do not address the issues directly and neither do they alter my primary conclusion - that this method is not going to be useful clinically. Arbitrary selection of miRNAs is not acceptable Tumours have not been characterised adequately Therefore my opinion on this MS is unaltered - personally I don’t think that these data merit publication

Reviewer 4 Report

Authors have properly addressed my comments.

Back to TopTop